ReviewJournal of hematology & oncology2022

Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.

Razan Mohty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.